Thromboembolic Complications After Pacemaker or Implantable Cardioverter-Defibrillator Procedures
Thromboembolic Complications Associated With Pacemaker or Implantable Cardioverter-Defibrillator Procedures: a Prospective Registry
調査の概要
詳細な説明
More than 235.500 cardiac pacemakers and cardioverter-defibrillators are implanted in the US every year, with an estimated 25,000 new implants in Brazil. Despite its proven clinical effectiveness and efficacy for a number of clinical conditions such as arrhythmias, the number of adverse events in the post-implant period remains substantial. Among these complications, venous obstructions occurs anywhere between 14% and 64% of all patients, causing devastating consequences such as upper extremity deep venous thrombosis and pulmonary embolism, ultimately leading to either significant impairment or death. Although retrospective studies have demonstrated the high incidence of these complications, as a consequence of a paucity of reliable registries we know next to nothing regarding how these venous lesions may influence the clinical outcome and mortality of patients, whether laboratorial markers may contribute to the early diagnosis of venous thrombosis and its complications, and about properties of diagnostic imaging for the identification of thromboembolic complications after permanent transvenous leads implantation.
The objective of this study is therefore to propose a significant improvement in an existing clinical database located within the Heart Institute (INCOR) at the University of Sao Paulo to enable the provision of answers to a clinical, biomarker, and imaging-related research questions. Specifically, our aims are to:
- Aim 1 - Registry infrastructure: In collaboration with professors from Duke University, we will create a series of improvements to the current database to enable it to serve as a platform not only for the current studies but also for future longitudinal, randomized studies. These include the standardization of variables in accordance with international guidelines, increase in patient retention and the ability to have additional data points in-between clinical appointments, improvement in the determination of cause of mortality, data quality monitoring, the creation of an item bank to measure aspects of quality of life that are specific for this population, as well as the integration of images and biomarkers to the clinical database.
- Aim 2 - Diagnostic imaging methods: To identify the incidence of upper extremity deep venous thrombosis after cardiac devices implantations or reoperation procedures, as well, the incidence of symptomatic and asymptomatic pulmonary thromboembolism.
- Aim 3 - Prognostic clinical factors: To study the impact of thromboembolic complications in the clinical prognostic and mortality of patients;
- Aim 4 - Prognostic biomarkers: To determine the association between the biomarkers related with alterations in the hemostasis system and the occurrence of venous thrombosis (biomarkers: Fibrinogen, D Dimer, Antithrombin, Prothrombin fragment 1 +2, thromboxane B, Platelets, Plasminogen)
At the end of this study we will have a registry with one of the largest number of patients with this condition around the world, fully equipped for future randomized controlled trials. We will also have a much better understanding regarding clinical, imaging, and biomarkers for this condition.
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
São Paulo、ブラジル、05403-900
- 募集
- Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
-
コンタクト：
- Katia R Silva, RN PhD
- 電話番号：5284 55-11-2661
- メール：katia.regina@incor.usp.br
-
主任研究者：
- Roberto Costa, MD PhD
-
主任研究者：
- Katia R Silva, RN PhD
-
副調査官：
- Martino Martinelli Filho, MD PhD
-
副調査官：
- Mario Terra Filho, MD PhD
-
副調査官：
- Wilson Mathias Jr, MD PhD
-
副調査官：
- Marta F Lima, MD PhD
-
副調査官：
- Roberto A Rached, MD PhD
-
副調査官：
- Claudio L Lucarelli, MD PhD
-
副調査官：
- Francisco C Carnevale, MD PhD
-
副調査官：
- Airton M Moreira, MD PhD
-
副調査官：
- Wagner T Tamaki, MD PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Older than 18 years
- Pacemaker/ implantable-cardioverter defibrillator (ICD) / cardiac resynchronization therapy (CRT) initial implant by transvenous approach or
- Patients submitted to reoperation procedures, as: pulse generator replacement, implant of an additional lead, lead extraction, lead repositioning;
- Subject agreed to participate and signed the consent form
Exclusion Criteria:
- Patients with a history of venous thromboembolism, coagulopathy or malignancy
- Pregnancy
- Life expectancy of less than one year
- Contraindication to administration of iodinated contrast (creatinine > 3.0)
- Unable to attend the follow-up appointments
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Implantation Procedures
Patients submitted to initial pacemaker or ICD implantation
|
|
Reoperation Procedures
Patients submitted to pacemaker or implantable cardioverter-defibrillator generator replacements, upgrade procedures and lead extraction
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Thromboembolic complications
時間枠：Participants will be evaluated at 1, 6, 12 months after the surgical procedure
|
Upper extremity deep venous thrombosis Pulmonary embolism All cause mortality
|
Participants will be evaluated at 1, 6, 12 months after the surgical procedure
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Venous lesions
時間枠：Participants will be evaluated at 12 months after the surgical procedure
|
Venous stenosis (any degree) detected by subtraction venography
|
Participants will be evaluated at 12 months after the surgical procedure
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者：Katia R Silva, RN PhD、University of Sao Paulo
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。